Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Peptides. Author manuscript; available in PMC 2010 May 1.
Published in final edited form as:
PMCID: PMC2749976

Leptin increases osteoblast-specific osteocalcin release through a hypothalamic relay 1


Enhanced long-term expression of leptin by gene therapy selectively in the hypothalamus, without leakage to the systemic circulation, abrogated skeletal abnormalities and reinstated weight and insulin-glucose homeostasis in leptin deficient ob/ob mice. Whether increases in osteocalcin, a hormone produced by osteoblasts and known to play a role in bone growth and recently in glucose-insulin homeostasis, may link these benefits of central leptin was assessed. The effects of a single intraventricular injection of non-immunogenic, non-pathogenic recombinant adeno-associated virus vector encoding leptin gene (rAAV-lep) or green fluorescent protein gene (rAAV-GFP, control) were studied in three genotypes, wildtype (wt), obese diabetic, hyperinsulinemic ob/ob and non-obese, diabetic insulinopenic Akita mice. Selective hypothalamic leptin expression with central rAAV-lep treatment decreased weight, fat mass, food intake, suppressed insulin levels in ob/ob and wt mice, and conferred euglycemia by suppressing blood glucose in all three genotypes. Contemporaneously, rAAV-lep treatment also augmented blood osteocalcin levels. In wt mice, osteocalcin rose by 51% and, whereas, basal osteocalcin levels in ob/ob and Akita mice were significantly lower as compared to those in wt mice (26% and 55%, respectively), gene therapy reinstated levels to the control range in ob/ob mice, and raised 40% above the wt range even in the absence of insulin in Akita mice. These findings demonstrate that the central beneficial effects of leptin on bone growth involve increased hypothalamic relay of signals that augment osteocalcin efflux from osteoblasts into the general circulation, a response that, in turn, may also modulate glucose-insulin and weight homeostasis.

Keywords: Osteocalcin, Osteoblast, Leptin, Hypothalamus, Bone remodeling, Glucose-insulin homeostasis

1. Introduction

Bones are constantly remodeled through a normally balanced process of bone resorption by osteoclasts and bone formation by osteoblasts [32,35,36,51,54,58]. Osteocalcin, secreted selectively by osteoblasts, is the most abundant non-collagenous protein in bone and dentin and comprises about 2% of total protein in the human body. Although increased osteocalcin secretion by osteoblastic cells is observed during the bone formation process, its precise role in bone remodeling remains to be ascertained [24,32,36,46,51,54]. Relative to wild type (wt) mice, osteocalcin null mice exhibited increased bone mass [18,24,32,46,51,64]. Intriguingly, these osteocalcin deficient mice became obese with age and concomitantly displayed decreased circulating insulin levels with hyperglycemia [28,32,46,64]. Administration of osteocalcin improved insulin-glucose homeostasis and stimulated insulin secretion in vitro from pancreatic β-cells of these mice. Although these observations taken together suggested a role for osteocalcin in energy homeostasis and bone remodeling, whether the pathways mediating this coupling reside in the periphery or brain is not known.

Leptin, produced primarily by adipocytes, is a pleiotropic hormone [1,2,8,10,14,19,21,29,37]. In the periphery, leptin modulates immune system, reproduction, angiogenesis and lipolysis, among others [8,16,19,37,47,56]. Centrally, leptin is an essential component of the feedback circuitry that integrates energy homeostasis, primarily by modulating the hypothalamic peptidergic network involved in energy intake and expenditure [14,20,29,3739,41,65]. In the absence of leptin the mutant ob/ob mice display a spectrum of metabolic disorders, including unremitting hyperphagia culminating in morbid obesity, hyperglycemia and hyperinsulinemia, and leptin replacement either peripherally or centrally readily corrects these metabolic abnormalities [10,12,14,20,21,29,37,40,41,45,59,60].

In addition, it became apparent recently that leptin may play a role in bone remodeling by mobilizing leptin receptors expressed by cells in bones and/or neurons in the hypothalamus [2326,28,31,35,36,51,54,58,63]. Leptin deficient ob/ob mice exhibit a phenotype with varied skeletal abnormalities characterized by reduced bone length, but increased cancellous bone mass as compared to wt mice [23,24,28,31,35,36]. Leptin replacement by either peripheral or central routes corrected this skeletal phenotype [18,23,24,26,31,35,36,46,58,64]. Given the experimental evidence that leptin administered centrally is readily transported to the peripheral circulation [7,42,43,49,53], the identity of central versus peripheral leptin receptors involved in reinstating the skeletal phenotype remains to be ascertained [35,36].

We have recently employed leptin gene transfer technology to increase leptin availability in the hypothalamus [1,2,10,11,20,21,40,59,60]. A single intracerebroventricular (icv) administration of a non-replicative, non-immunogenic and non-pathogenic adeno-associated virus vector encoding leptin gene (rAAV-lep) augmented leptin availability selectively in the hypothalamus for the lifetime of the rodents. We observed that, in addition to reversing obesity and metabolic disorders, this selective reinstatement of leptin action in the hypothalamus abrogated abnormalities in bone architecture, and restored the skeletal phenotype in ob/ob mice to values that did not differ from wt mice [35,36]. Leptin was undetectable in the rAAV-lep treated ob/ob mice, thereby reinforcing the view that activation solely of leptin-responsive neural pathways in the hypothalamus resulted in normalization of skeletal phenotype and that leptin may normally be required for optimal peak bone growth and quality [36,37].

In view of this emerging evidence linking osteoblast specific osteocalcin and adipocyte leptin as key players in integration of energy homeostasis and bone volume and architecture, we undertook to investigate the relationship between leptin and osteocalcin, if any, in manifestation of central effects of leptin on energy balance and skeletal phenotype [24,28,46,64]. In the current study, we took advantage of single icv administration of rAAV-lep paradigm to selectively raise leptin levels in the hypothalamus of three genotypes; the leptin-deficient hyperinsulinemic and hyperglycemic ob/ob [10,12,3537,40,59,60], the insulinopenic non-obese Akita [59,60,62,66], and wt mice in attempts to assess the effects of leptin on circulating osteocalcin levels in relation with its impact on body weight, adiposity, energy intake, and metabolic indicators, blood insulin and glucose levels.

2. Methods

2.1 Experimental design

The effects of icv rAAV-lep on body weight (BW), food intake (FI) and blood levels of osteocalcin, insulin and glucose in three genotypes, ob/ob, Akita and wt mice were examined as follows.

Mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and housed individually in a temperature (21° C) and light controlled room (lights-on 06:00–18:00h) under specific pathogen-free conditions. Regular chow diet (11 Kcal% fat; caloric density 3.4 Kcal/g; LM-485 Teklad, Madison, WI) and water were available ad libitum. Mice were adapted to the animal rooms for one week before experimental procedures were begun. BW and FI were measured on a weekly basis throughout the experiment to monitor the condition of the animals and confirm the effectiveness of the treatments. The BW data in ob/ob mice have been published elsewhere [22]. Only the BW recorded at the time of sacrifice and food consumed the week prior to the day of sacrifice in these three animal models are presented here. The Institutional Animal Care and Use Committee of the University of Florida approved the animal protocols.

In three separate experiments, 4 weeks old male ob/ob mice (27–31 g) and age-matched control C57 male mice (16–18 g) in the first experiment, 4–10 weeks old Akita mice, as available (15–20 g), along with their wt male control littermates (18–22 g) in the second experiment, and normal adult male C57 wt mice of varying ages (21–28g) in the final experiment, were employed.

2.2 Surgical procedure

Mice were anesthetized by intraperitoneal injection of sodium pentobarbital (90 mg/kg for wt and ob/ob mice and 80mg/kg for the lean Akita mice). They were placed in a stereotaxic instrument for intracerebral injection of either a non-immunogenic, non-pathogenic rAAV encoding the green fluorescent protein gene (rAAV-GFP, 1.8 × 1010 particles in 1.5 μl) or rAAV encoding the rat leptin gene (rAAV-lep, 2.4 × 1010 particles in 1.5 μl) as described earlier [10,12,59,60]. The vectors used were packaged, purified, concentrated and titered as previously described [20,21,40]. The stereotaxic coordinates for third ventricle injections were on the midline, 0.3mm posterior of bregma, and 4.2mm below the dura [10,12,59,60]. The rAAV-GFP or rAAV-lep solution was slowly infused over a 2 minute period and the injector was left in place for an additional 5 minutes to allow diffusion of the injected solution. The age-matched wt mice in the ob/ob and Akita mouse experiments were left untreated to serve as additional controls.

The ob/ob mice were sacrificed 13 weeks, Akita mice 9–10 weeks and wt mice 3 weeks post-icv injection. On the day of sacrifice mice were anesthetized with sodium pentobarbital for withdrawal of blood by orbital sinus puncture as described [10,59,60], and then killed by decapitation between 10:30 and 15:00 h. Abdominal WAT was dissected out and weighed. Blood glucose was measured at sacrifice with a drop of blood from the orbital sinus using a glucose meter (Glucometer Elite XL; Bayer, Elkhart, IN). Plasma was stored at −20° C for analysis of osteocalcin by IRMA kit (ALPCO Diagnostics, Salem, NH) and insulin by RIA kit (Sensitive Rat Insulin RIA kit, Linco Research, Inc., St. Charles, MO), as described earlier [10,59,60].

2.3 Statistical analyses

The results from the ob/ob and Akita mice were analyzed using one-way ANOVA and Newman-Keuls multiple comparison post-hoc tests. The results from the wt mice experiment were analyzed using Student’s t-test. The significance was set at p<0.05 for all analyses.

3. Results

3.1 Effects of rAAV-lep on BW, Visceral WAT mass and FI

As evident in Fig. 1A, a single rAAV-lep icv injection suppressed BW in obese ob/ob and wt mice as compared to their respective rAAV-GFP controls (p<0.05). In fact, BW in rAAV-lep treated ob/ob mice was rapidly normalized to that found in the age-matched wt mice [22]. However, as observed earlier [60], BW in Akita mice after rAAV-lep injection was not affected (Fig. 1A, p>0.05).

Figure 1
The effects of icv rAAV-lep injection in ob/ob, Akita and wt mice on body weight (A), visceral WAT (B) and food intake (C). Body weight and visceral WAT data represent the values at the time of sacrifice and the food intake data represents cumulative ...

In conjunction with suppression of BW, visceral WAT was also significantly reduced in ob/ob and wt mice after rAAV-lep treatment (Fig. 1B, p<0.05). The WAT mass of rAAV-GFP treated ob/ob mice was more than 12 times that of age-matched untreated wt control mice (p<0.01), which was reduced to the control range after rAAV-lep treatment. In contrast, WAT was indiscernible for measurement in both rAAV-GFP control and rAAV-lep treated Akita mice.

In association with rAAV-lep induced diminution in BW and WAT mass, hyperphagia seen in rAAV-GFP ob/ob mice was suppressed and the cumulative FI during the week preceding the termination of the experiment was normalized by rAAV-lep injection (Fig. 1C, p<0.05). Similarly, hyperphagia in Akita mice receiving rAAV-GFP, as indicated by higher cumulative FI (49%) compared to that of their wt littermates, was suppressed to the control range after rAAV-lep injection (Fig. 1C, p<0.05). In wt mice, cumulative FI was also significantly reduced by rAAV-lep injection (Fig. 1C, p<0.05).

3.2 Effects of rAAV-lep on circulating insulin and glucose levels

In hyperinsulinemic ob/ob mice, rAAV-lep suppressed blood insulin levels to the range significantly below that observed in wt untreated control mice (Fig. 2A, inset). Plasma insulin in Akita mice was undetectable (not shown). As reported earlier [10,59,60], plasma insulin levels were significantly reduced in wt mice after rAAV-lep injection (Fig. 2C, inset p<0.01).

Figure 2
The effects of icv rAAV-lep on blood glucose in ob/ob (A), Akita (B) and wt (C) mice and plasma insulin levels (inset) in ob/ob (A) and wt mice (C) at the time of sacrifice. Insulin was undetectable in Akita mice.

Hyperglycemia was also abrogated and euglycemia prevailed after rAAV-lep injection in ob/ob and Akita mice (Fig, 2A and B, p<0.05). Also, blood glucose levels in ob/ob rAAV-lep injected mice fell below those seen in control untreated mice (Fig. 2A, p<0.05). As expected [10,59,60], rAAV-lep suppressed plasma glucose in control wt mice (Fig. 2C). It should be noted that reduction in blood glucose response was contemporaneous with suppressed plasma insulin levels in both ob/ob and wt mice after rAAV-lep injection.

3.3 Effects of rAAV-lep on plasma osteocalcin levels

Unlike suppression of blood glucose and insulin responses, rAAV-lep injection elicited an opposite osteocalcin response in all three genotypes. In rAAV-GFP treated ob/ob mice, basal osteocalcin levels were significantly lower (26%) than in wt untreated control mice (Fig. 3A, p<0.05) and rAAV-lep treatment reinstated osteocalcin levels to the range seen in controls (p<0.01). Similarly, osteocalcin levels in insulin-deficient rAAV-GFP injected Akita mice were 55% below those in wt untreated controls (Fig. 3B, p<0.001), and rAAV-lep injection stimulated them above those observed in rAAV-GFP treated Akita mice (p<0.001). In fact, unlike the reinstatement response seen in ob/ob mice, rAAV-lep in Akita mice raised osteocalcin levels to a 40% higher range than in untreated wt littermates (p<0.01). Also, rAAV-lep injection in the wt mice was effective in eliciting a significant increase (51%) in circulating osteocalcin levels over that found in controls (Fig. 3C, p<0.05).

Figure 3
The effects of icv rAAV-lep on plasma osteocalcin levels in ob/ob (A), Akita (B) and wt (C) mice at the time of sacrifice.

4. Discussion

In accord with previous reports [1012,21,50,59,60], increased leptin transgene expression to augment the supply of biologically active leptin within the hypothalamus by icv rAAV-lep injection, suppressed BW, adiposity and FI, and blood insulin levels concomitant with sustenance of euglycemia in leptin-deficient hyperinsulinemic ob/ob mice and wt mice. In leptinopenic and hyperglycemic Akita mice, central leptin gene therapy similarly attenuated BW and hyperphagia and engendered euglycemia even in the absence of detectable insulin [60]. The possibility that these long-term benefits on energy homeostasis may be attributed to diminished energy consumption and increased energy expenditure, in conjunction with markedly suppressed fat depot due to decreased availability of adipogenic insulin and increased energy metabolism, has been previously addressed [1,2,17,20,21,33,3740,55,59,60].

We now report that by similarly enhancing leptin signaling in the hypothalamus one can increase blood levels of osteocalcin secreted from osteoblasts of all three genotypes. Leptin infusion centrally in rats attenuated the calorie-restriction induced decrease in blood osteocalcin levels, an observation suggestive of the stimulatory effects of leptin on osteocalcin levels [30]. Furthermore, we report for the first time that either in the complete absence, as in ob/ob mice, or markedly diminished circulating leptin levels, as in Akita mice, secretion of osteocalcin is significantly less than that in wt mice. Additionally, whereas leptin expression centrally reinstated osteocalcin levels in ob/ob mice to the normal control range, a similar enhanced leptin signaling in Akita mice elevated osteocalcin levels significantly above the normal circulating range in wt mice. Seemingly, leptin can act centrally to augment osteocalcin secretion by osteoblasts, and this centrally mediated stimulatory response may not require insulin participation, as illustrated by Akita mice. Interestingly, parathyroid hormone and simvastatin are the other therapies that have been found to increase osteoblast activity [15,27,52,63]. The possibility that increased central leptin action may participate in stimulation of osteocalcin by these therapies is under investigation.

Convergence of evidence in recent years is in line with the view that central leptin feedback is an important pathway in linking energy homeostasis and bone remodeling [26,31,35,36,46,63,64]. Indeed, skeletal abnormalities, the hallmark of leptin mutant ob/ob mice, can be alleviated by leptin replacement peripherally, presumably, in this case, by the active leptin transfer across the BBB to hypothalamic targets [7,42,43]. We reported that icv rAAV-lep-induced leptin gene expression selectively in the hypothalamus rescued the ob/ob skeletal phenotype by promoting growth in femoral length and total bone volume, along with decreasing the femoral and vertebral cancellous bone volume to that observed in wt mice [35,36]. A similar reduction in cancellous bone volume in vertebrae was also seen after icv infusion of leptin in a short-term experiment [23,31]. The current observation of high osteocalcin levels in circulation in association with normalization of cortical as well as cancellous bone volume [35,36], strongly imply a permissive role of central leptin in bone remodeling, in part, conferred by increased osteocalcin secretion from osteoblasts in ob/ob mice. Whether high circulating osteocalcin levels in Akita mice and wt mice after icv rAAV-lep administration exert similar positive effects remains to be determined.

There are few studies examining the causal interaction among various metabolic markers in the periphery conferred by leptin. Lee and Karsenty [46] recently reported that mice lacking osteocalcin display hyperglycemia in association with markedly reduced blood insulin levels, decreased pancreatic islet cell size and insulin immunoreactivity in pancreatic β-cells (Fig. 4A). That osteocalcin deficiency underlies the disruptions in glucose-insulin homeostasis was underscored by the finding that osteocalcin administration increased insulin secretion from β-cells and normalized blood glucose levels. In contrast, we have consistently observed that enhanced expression of leptin in the hypothalamus suppressed pancreatic insulin secretion and blood glucose levels concomitantly with fat depletion [1,2,10,22,37,40,45]. Our current finding that elevated osteocalcin levels are associated with suppressed blood insulin levels is not consistent with the proposed stimulatory role of osteocalcin on pancreatic insulin secretion [34,46]. It is plausible that increased leptin signaling from hypothalamus to pancreatic β-cells restrains insulin secretion to an extent that it is not overcome by high circulating levels of osteocalcin or the osteocalcin stimulatory and insulin inhibitory responses are independently propagated by central leptin feedback (Fig. 4B).

Figure 4
Regulation of circulating levels of osteocalcin and insulin by leptin. A. Lee and Karsenty [46] proposed that a deficit in leptin signaling in the hypothalamus stimulates osteocalcin release from skeletal osteoblasts that, in turn, augments insulin secretion ...

Despite suppression of circulating insulin, however, rAAV-lep treatment was also shown to increased insulin sensitivity in all three genotypes [10,59,60]. Osteocalcin administration was also shown to enhance insulin sensitivity in osteocalcin-mutant mice [34,46]. Thus, it is possible that the rAAV-lep evoked increased insulin sensitivity is, in part, conferred by elevated osteocalcin levels. In that case, how rises in circulating osteocalcin impart increased insulin sensitivity independent of insulin, as in Akita mice [59], remains to be understood.

In this context, the possibility that stimulation by osteocalcin of adiponectin secretion from adipocytes contributed to enhanced insulin sensitivity was also advanced [28,46]. However, we found that central leptin gene therapy enhanced insulin sensitivity contemporaneously with suppressed blood adiponectin levels [59]. Seemingly, the mechanism(s) responsible for increasing insulin sensitivity in these paradigms are complex and varied and likely to include those that exclude increased adiponectin secretion.

How abrogation of hyperglycemia in ob/ob and Akita mice and suppression of blood glucose in wt mice contemporaneous with high circulating osteocalcin levels after icv rAAV-lep treatment is causally related, is not clear. Increased leptin signaling by icv injection of either leptin or rAAV-lep readily augments energy expenditure and glucose metabolism, even in the absence of increased energy intake [1,2,17,20,21,32,59,60] and these centrally generated effects participate substantially in diminishing blood glucose levels [20,21,59,60]. Therefore, the question of whether increases in osteocalcin, in turn, modulates glucose homeostasis either independently or in concert with increased energy expenditure imposed by stimulation of hypothalamic leptin receptors is under investigation.

Finally, It is likely that hypothalamic leptin target sites involved in energy homeostasis are a part of the substrate network that also modulates osteocalcin secretion from osteoblasts [3741,65]. Central leptin gene therapy reliably repressed orexigenic NPYergic signaling by decreasing hypothalamic NPY gene expression and release [3941]. The NPY receptor system in the hypothalamus has also been implicated in bone remodeling [35,48]. Indeed, deletion of hypothalamic Y2 and Y4 NPY receptors impacted bone and adipose tissue in varied ways [35,48]. Therefore, we propose that the effects of central leptin therapy on bone remodeling are mediated by hypothalamic NPYergic signaling involving Y2 and Y4 receptors.

The descending efferent pathways from hypothalamus that relay leptin-induced signals to promote osteocalcin secretion from osteoblasts, remain to be deciphered (Fig. 4B). It is possible that sympathetic innervations from hypothalamus transmit these signals to bone cells in the periphery [9,13,34,57]. Based on the fact that track-tracing investigations have mapped distinct hypothalamic neural links to those organs in the periphery, such as WAT [44], brown adipose tissue [6,9], pancreas [13,46] and liver [44,61], that participate in the integration of energy balance by leptin, one can speculate that a similar discrete descending neural pathway between leptin-responsive hypothalamic neurons and bone cells is involved in the osteoblast activation (Fig. 4B). Furthermore, since leptin also modulates various neuroendocrine functions [3741], the additional possibility that these may secondarily assist in stimulation of osteocalcin deserves consideration.

In summary, the present study clearly demonstrates that leptin can stimulate osteoblast-specific osteocalcin secretion by involving receptors exclusively resident in the hypothalamus and this response may, in part, underlie the well-documented benefits of leptin on skeletal architecture and energy homeostasis.


This research was supported by a grant from the National Institutes of Health (DK37273).


1Presented at the 90th Annual Meeting of The Endocrine Society, San Francisco, CA, June 15–18, 2008.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Bagnasco M, Dube MG, Kalra PS, Kalra SP. Evidence for the existence of distinct central appetite and energy expenditure pathways and stimulation of ghrelin as revealed by hypothalamic site-specific leptin gene therapy. Endocrinology. 2002;143:4409–21. [PubMed]
2. Bagnasco M, Dube MG, Katz A, Kalra PS, Kalra SP. Leptin expression in hypothalamic PVN reverses dietary obesity and hyperinsulinemia but stimulates ghrelin. Obesity Research. 2003;11:1463–70. [PubMed]
3. Baldock PA, Allison SJ, Lundberg P, Lee NJ, Slack K, Lin EJ, et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. Journal of Biological Chemistry. 2007;282:19092–102. [PubMed]
4. Baldock PA, Sainsbury A, Allison S, Lin EJD, Couzens MDB, Enriquez R, et al. Hypothalamic control of bone formation: distinct actions of leptin and Y2 receptor pathways. J Bone Miner Res. 2005;20:1851–57. [PubMed]
5. Baldock PA, Sainsbury A, Couzens M, Enriquez R, Thomas GP, Gardiner EM, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest. 2002;109:915–21. [PMC free article] [PubMed]
6. Bamshad M, Song CK, Bartness TJ. CNS origins of the sympathetic nervous system outflow to brown adipose tissue. Am J Physiol. 1999;276:R1569–78. [PubMed]
7. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides. 1996;17:305–11. [PubMed]
8. Baratta M. Leptin--from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monit. 2002;8:RA282–RA292. [PubMed]
9. Bartness TJ, Kay Song C, Shi H, Bowers RR, Foster MT. Brain-adipose tissue cross talk. Proc Nutr Soc. 2005;64:53–64. [PubMed]
10. Boghossian S, Dube MG, Torto R, Kalra PS, Kalra SP. Hypothalamic clamp on insulin release by leptin-transgene expression. Peptides. 2006;27:3245–54. [PubMed]
11. Boghossian S, Lecklin AH, Torto R, Kalra PS, Kalra SP. Suppression of fat deposition for the life time of rodents with gene therapy. Peptides. 2005;26:1512–19. [PubMed]
12. Boghossian S, Ueno N, Dube MG, Kalra PS, Kalra SP. Leptin gene transfer in the hypothalamus enhances longevity in adult monogenic mutant mice in the absence of circulating leptin. Neurobiol Aging. 2007;28:1594–604. [PubMed]
13. Buijs RM, Chun SJ, Niijima A, Romijn HJ, Nagai K. Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. J Comp Neurol. 2001;431:405–23. [PubMed]
14. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks [see comments] Science. 1995;269:546–49. [PubMed]
15. Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab. 2001;86:4556–59. [PubMed]
16. Chen Y, Heiman ML. Chronic leptin administration promotes lipid utilization until fat mass is greatly reduced and preserves lean mass of normal female rats. Regul Pept. 2000;92:113–19. [PubMed]
17. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin- deficient diabetes in the rat. Diabetes. 1999;48:1487–92. [PubMed]
18. Cirmanova V, Bayer M, Starka L, Zajickova K. The effect of leptin on bone--an evolving concept of action. Physiological Research. 2008;57:S143–S151. [PubMed]
19. Della-Fera MA, Choi YH, Hartzell DL, Duan J, Hamrick M, Baile CA. Sensitivity of ob/ob mice to leptin-induced adipose tissue apoptosis. Obes Res. 2005;13:1540–47. [PubMed]
20. Dhillon H, Ge Y, Minter RM, Prima V, Moldawer LL, Muzyczka N, et al. Long-term differential modulation of genes encoding orexigenic and anorexigenic peptides by leptin delivered by rAAV vector in ob/ob mice. Relationship with body weight change. Regul Pept. 2000;92:97–105. [PubMed]
21. Dhillon H, Kalra SP, Prima V, Zolotukhin S, Scarpace PJ, Moldawer LL, et al. Central Leptin Gene Therapy Suppresses Body Weight Gain, Adiposity and Serum Insulin Without Affecting Food Consumption in Normal Rats: A Long-Term Study. Regul Pept. 2001;99:69–77. [PubMed]
22. Dube MG, Torto R, Kalra SP. Increased leptin expression selectively in the hypothalamus suppresses inflammatory markers CRP and IL-6 in leptin-deficient diabetic obese mice. Peptides. 2008;29:593–98. [PMC free article] [PubMed]
23. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell. 2000;100:197–207. [PubMed]
24. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, et al. Increased bone formation in osteocalcin-deficient mice. Nature. 1996;382:448–52. [PubMed]
25. Ealey KN, Fonseca D, Archer MC, Ward WE. Bone abnormalities in adolescent leptin-deficient mice. Regul Pept. 2006;136:9–13. [PubMed]
26. Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Ae Kim C, et al. Serum leptin level is a regulator of bone mass. PNAS. 2004;101:3258–63. [PubMed]
27. Evans RM, Grey A, Clarke BL. Three perspectives on thiazolidine and bone health. Endocrine News. 2008:14–21.
28. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. PNAS. 2008;105:5266–70. [PubMed]
29. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763–70. [PubMed]
30. Guidobono F, Pagani F, Sibilia V, Netti C, Lattuada N, Rapetti D, et al. Different skeletal regional response to continuous brain infusion of leptin in the rat. Peptides. 2006;27:1426–33. [PubMed]
31. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res. 2005;20:994–1001. [PubMed]
32. Harada S-i, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003;423:349–55. [PubMed]
33. Hidaka S, Yoshimatsu H, Kondou S, Tsuruta Y, Oka K, Noguchi H, et al. Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. Faseb J. 2002;16:509–18. [PubMed]
34. Hinoi E, Gao N, Jung DY, Yadav V, Yoshizawa T, Myers MG, Jr, et al. The sympathetic tone mediates leptin’s inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol. 2008;183:1235–42. [PMC free article] [PubMed]
35. Iwaniec UT, Boghossian S, Lapke PD, Turner RT, Kalra SP. Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice. Peptides. 2007;28:1012–19. [PMC free article] [PubMed]
36. Iwaniec UT, Dube MG, Boghossian S, Song H, Helferich WG, Turner RT, et al. Body mass influences cortical bone mass independent of leptin signaling. Bone. 2009;44:404–12. [PMC free article] [PubMed]
37. Kalra SP. Central leptin insufficiency syndrome: An interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions. Peptides. 2008;29:127–38. [PMC free article] [PubMed]
38. Kalra SP. Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: New therapeutic approaches. Nutrition. 2008;24:820–26. [PMC free article] [PubMed]
39. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev. 1999;20:68–100. [PubMed]
40. Kalra SP, Kalra PS. Gene transfer technology: a preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life-expectancy. Trends Pharmacol Sci. 2005;26:488–95. [PubMed]
41. Kalra SP, Kalra PS. NPY and Cohorts in Regulating Appetite, Obesity and Metabolic Syndrome: Beneficial Effects of Gene Therapy. Neuropeptides. 2004;38:201–11. [PubMed]
42. Kastin AJ, Pan W. Dynamic regulation of leptin entry into brain by the blood-brain barrier. Regul Pept. 2000;92:37–43. [PubMed]
43. Kastin AJ, Pan W. Intranasal leptin: blood-brain barrier bypass (BBBB) for obesity? Endocrinology. 2006;147:2086–87. [PubMed]
44. Kreier F, Kap YS, Mettenleiter TC, van Heijningen C, van der Vliet J, Kalsbeek A, et al. Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology. 2006;147:1140–47. [PubMed]
45. Lecklin AH, Dube MG, Torto R, Kalra PS, Kalra SP. Perigestational suppression of weight gain with central leptin gene therapy results in lower weight F1 generation. Peptides. 2005;26:1176–87. [PubMed]
46. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab. 2008;19:161–6. [PubMed]
47. Lord G. Role of leptin in immunology. Nutr Rev. 2002;60:S35–38. S68–87. [PubMed]
48. Lundberg P, Allison SJ, Lee NJ, Baldock PA, Brouard N, Rost S, et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. Journal of Biological Chemistry. 2007;282:19082–91. [PubMed]
49. Maness LM, Kastin AJ, Farrell CL, Banks WA. Fate of leptin after intracerebroventricular injection into the mouse brain. Endocrinology. 1998;139:4556–62. [PubMed]
50. Otukonyong EE, Dube MG, Torto R, Kalra PS, Kalra SP. Central Leptin Differentially Modulates Ultradian Secretory Patterns of Insulin, Leptin and Ghrelin Independent of Effects on Food Intake and Body Weight. Peptides. 2005;26:2559–66. [PubMed]
51. Patel MS, Elefteriou F. The new field of neuroskeletal biology. Calcified Tissue International. 2007;80:337–47. [PubMed]
52. Ruiz-Gaspa S, Nogues X, Enjuanes A, Monllau JC, Blanch J, Carreras R, et al. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. Journal of Cellular Biochemistry. 2007;101:1430–38. [PubMed]
53. Sahu A. Resistance to the satiety action of leptin following chronic central leptin infusion is associated with the development of leptin resistance in neuropeptide Y neurones. J Neuroendocrinol. 2002;14:796–804. [PubMed]
54. Seeman E. Structural basis of growth-related gain and age-related loss of bone strength. Rheumatology. 2008;47:iv2–iv8. [PubMed]
55. Shi ZQ, Nelson A, Whitcomb L, Wang J, Cohen AM. Intracerebroventricular administration of leptin markedly enhances insulin sensitivity and systemic glucose utilization in conscious rats. Metabolism. 1998;47:1274–80. [PubMed]
56. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. Science. 1998;281:1683–86. [PubMed]
57. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305–17. [PubMed]
58. Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Current Opinion in Pharmacology. 2004;4:295–300. [PubMed]
59. Ueno N, Dube MG, Inui A, Kalra PS, Kalra SP. Leptin modulates orexigenic effects of ghrelin and attenuates adiponectin and insulin levels and selectively the dark-phase feeding as revealed by central leptin gene therapy. Endocrinology. 2004;145:4176–84. [PubMed]
60. Ueno N, Inui A, Kalra SP, Kalra PS. Leptin transgene expression in the hypothalamus enforces euglycemia in diabetic, insulin-deficient nonobese Akita mice and leptin-deficient obese ob/ob mice. Peptides. 2006;27:2332–42. [PubMed]
61. Uyama N, Geerts A, Reynaert H. Neural connections between the hypothalamus and the liver. Anat Rec A Discov Mol Cell Evol Biol. 2004;280:808–20. [PubMed]
62. Wang J, Takeuchi T, Tanaka S, Kubo SK, Kayo T, Lu D, et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J Clin Invest. 1999;103:27–37. [PMC free article] [PubMed]
63. Whitfield JF. PTH and leptin: Two bone builders at the Alamo. Part 2: Leptin. 2002 medscape, com.
64. Wolf G. Energy regulation by the skeleton. Nutrition Reviews. 2008;66:229–33. [PubMed]
65. Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol. 2005;184:291–318. [PubMed]
66. Yoshioka M, Kayo T, Ikeda T, Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes. 1997;46:887–94. [PubMed]